News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 53962
- Sources here
- 21
- Companies here
- 33
Active search
53962 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
What Is Behind The Latest Camden Property Trust (CPT) Update?
Camden Property Trust (CPT) has filed a shelf registration for up to 7,250,000 common shares, valued at approximately US$802.865 million, linked to an Employee Stock Ownership Plan. Despite recent short-term share price dips, the company shows steady longer-term returns and trades below analyst targets …
Fervo Energy Company (FRVO) loses nearly a quarter in weekly renewable-utilities slide
The geothermal stock’s latest move keeps pressure on the tape, with elevated activity but weak technical confirmation.
Westlake Corporation declares $0.533 dividend
* Westlake Corporation (WLK [https://seekingalpha.com/symbol/WLK]) declares $0.533/share quarterly dividend [https://seekingalpha.com/pr/20620238-westlake-corporation-declares-quarterly-dividend], 0.6% increase from prior dividend of $0.530. * Forward yield [https://seekingalpha.com/symbol/WLK/dividends/yield?source=news_bullet] 2.68% * Payable Sept. 10; for shareholders of record Aug. 25; ex-div Aug. 25. * See WLK Dividend Scorecard, Yield Chart, & Dividend …
Mercury Systems (MRCY) Q2 Earnings Report Preview: What To Look For
Mercury Systems (MRCY) Q2 Earnings Report Preview: What To Look For Aerospace and defense company Mercury Systems (NASDAQ:MRCY) will be reporting results this Tuesday afternoon. Here's what to look for. Mercury Systems beat analysts' revenue expectations last quarter, reporting revenues of $235.8 million, up …
Permian Basin Royalty Trust (NYSE:PBT): Why Is Energy Income in Focus Today?
Permian Basin Royalty Trust (NYSE:PBT) is under scrutiny as an energy income vehicle, with its latest update prompting an examination of how well its energy income is supported by operational execution rather than general market sentiment. The article emphasizes that for royalty trusts, cash …
Why Strategy (MSTR) Shares Are Trading Lower Today
Why Strategy (MSTR) Shares Are Trading Lower Today What Happened? Shares of bitcoin development company Strategy (NASDAQ:MSTR) fell 3.5% in the afternoon session after index provider MSCI proposed removing the company from its Global Investable Market Indexes, compounding concerns over recent sales of its …
RKLB Stock Rises Overnight: Rocket Lab’s First 8 Satellites From $143M Globalstar Deal Reach Orbit
Rocket Lab's stock (RKLB) rose overnight after the company confirmed that the first eight satellites built under its $143 million contract with MDA Space successfully reached orbit. These satellites, part of a 17-platform deal, will support Globalstar’s direct-to-device communications and IoT services. The successful …
Veeva’s 52% quarter rebuilds the recovery, but light volume and weak Relative Strength keep the signal mixed
Veeva Systems added 5.8% in the latest week and now trades 33.9% above its weekly Trend Line, yet participation remains below average and Relative Strength has not turned positive.
350 Patients Have Been Treated—Mesoblast’s Pain Data Come Next
Mesoblast (MESO) has completed patient treatment in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain associated with degenerative disc disease, treating 350 patients. The trial evaluates rexlemestrocel-L and targets a primary endpoint of durable pain reduction at 12 months. Top-line results …
Mesoblast completes patient treatment in phase 3 back pain trial By Investing.com
Mesoblast Limited has completed patient treatment in its phase 3 trial for rexlemestrocel-L, aimed at chronic low back pain associated with degenerative disc disease. The trial enrolled 350 patients and seeks to confirm durable pain reduction as its primary endpoint, with top-line results anticipated …
Mesoblast Achieves Major Milestone in Pivotal Phase 3 Chronic Low Back Pain Trial
Mesoblast Limited has completed patient treatment in its pivotal Phase 3 trial for chronic low back pain, with 350 patients receiving rexlemestrocel-L or a sham injection. This milestone moves the company closer to potential market entry for its allogeneic cellular medicine, which has RMAT …
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Limited NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic …